data quality - 医薬品医療機器総合機構 · evaluation and data reliability. it is...
TRANSCRIPT
![Page 1: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/1.jpg)
Data Quality
-from Inspectors’ Point of View-
Tomoko Ohsawa, Ph.D.
Director for GCP Inspection,
Office of Conformity Audit,
PMDA
![Page 2: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/2.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
• The views and opinions expressed in the following PowerPoint slides are those of the individual presenter and should not be attributed to Drug Information Association, Inc. (“DIA”), its directors, officers, employees, volunteers, members, chapters, councils, Special Interest Area Communities or affiliates, or any organization with which the presenter is employed or affiliated.
• These PowerPoint slides are the intellectual property of the individual presenter and are protected under the copyright laws of the United States of America and other countries. Used by permission. All rights reserved. Drug Information Association, Drug Information Association Inc., DIA and DIA logo are registered trademarks. All other trademarks are the
t f th i ti
Disclaimer
2
![Page 3: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/3.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
3
![Page 4: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/4.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
4
![Page 5: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/5.jpg)
Product Lifecycle
Quality Clinicaltrials
Approval
Post-marketingSurveillance
Nonclinical studies
Application for Re-examination
New-drugApplication
Pharmacovigilance
Result of Re-examination
![Page 6: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/6.jpg)
Evaluation and Data Reliability
It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the relevant product item shall be conducted on the basis of the data and materials attached to the application.
Safety
Efficacy
Compliance
Detection
![Page 7: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/7.jpg)
Evaluation ・・・with Unreliable Data?
Without Appropriate Safety Information ・・・
Inaccurate Data ・・・
Approved?
![Page 8: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/8.jpg)
Efficacy and Safety Cannot be Evaluated Appropriately!
More Effective and Safer Drug(s) Cannot be Conveyed promptly to the People who are waiting its(their) arrival.
![Page 9: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/9.jpg)
Evaluation and Data Reliability
It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the relevant product item shall be conducted on the basis of the data and materials with ensured reliability attached to the application.
Safety
Efficacy
Compliance
Detection
![Page 10: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/10.jpg)
( Approval to Marketing of Drugs, etc. )Article 14 (3)
A person who intends to obtain an approval under paragraph (1) shall attach data related to the results of the clinical study or any other materials to the application, as provided for by Ordinance of the Ministry of Health, Labour and Welfare. In such cases, when the drug or medical device pertaining to the application is any of those drugs or medical device specified by Ordinance of the Ministry of Health, Labour and Welfare, the data or materials shall be those collected and prepared in accordance with the standards specified by the Minister of Health, Labour and Welfare.
(For re-examination : Article 14-4)
The Pharmaceutical Affairs Act
10
![Page 11: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/11.jpg)
( Data Reliability Standards for Applications )Article 43The materials prescribed in the last sentence of paragraph (3) of Article 14 of the Act (including a case with application mutatis mutandis in paragraph (9) of Article 14) must be collected and prepared pursuant to the following items in addition to those specified in the Ordinance of Implementation Standards for Non-Clinical Studies on Safety of Drugs (Ordinance of Ministry of Welfare No.21 of 1997), the Ordinance of Implementation Standards for Clinical Studies on Drugs (Ordinance of Ministry of Welfare No.28 of 1997), the Ordinance of Implementation Standards for Nonclinical Studies Related to Safety of Medical Devices (Ordinance of Ministry of Health, Labour and Welfare No. 37 of 2005), and the Ordinance of Implementation Standards for Clinical Studies of Medical Devices (Ordinance of Ministry of Health, Labour and Welfare No. 36 of 2005). (to be continued)
Ordinance for Enforcement of the Pharmaceutical Affairs Act ①
11
![Page 12: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/12.jpg)
( Data Reliability Standards for Applications )Article 43
(i) The materials concerned must be prepared precisely in accordance with results provided in investigations or examinations carried out for the purpose of making this (Accuracy)
(ii) Upon investigations or examinations listed in the preceding item, if obtained results of the investigations or results of the examination etc. cast doubt on quality, effectiveness or safety of drugs or medical devices concerned pertaining to the application, results of investigation and results of the examination concerned must be examined and evaluated, and the outcome must be described in the materials concerned (Completeness, Integrity)
・The materials that form the basis for the materials concerned must be retained until the date when a decision is made on the approval pursuant to the provision of Article 14 of the Act (Retention)
(For re-examination : Article 61)
Ordinance for Enforcement of the Pharmaceutical Affairs Act ②
12
![Page 13: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/13.jpg)
Standards for Data Reliability GLP : Good Laboratory Practice (Ministerial
Ordinance) GCP : Good Clinical Practice (Ministerial
Ordinance)GPMSP : Good Post-marketing Surveillance
Practice (Ministerial Ordinance) GPSP : Good Post-marketing Study Practice
(Ministerial Ordinance)Data Reliability Standards for Applications
(Ordinance for Enforcement of the Pharmaceutical Affairs Act)
![Page 14: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/14.jpg)
( Approval to Marketing of Drugs, etc. )Article 14 (5)
In the review pursuant to the provision of paragraph (2), item (iii), examinations of the quality, efficacy and safety of the relevant product item (including examinations of the equivalence of ingredients, quantities, structure, dosage and administration, direction of use, indications, effects, performance, etc., to those of product items which have already been approved for manufacturing and sales) shall be conducted on the basis of the contents of the application for the item concerned as well as the data and materials provided for in the first sentence of paragraph (3). In such cases, when the product item concerned is any of those drugs or medical device specified by Ordinance of the Ministry of Health, Labour and Welfare as provided for in the second sentence of said paragraph, prior written or on-site examinations shall be conducted on whether the data and/or materials on the relevant product item comply with the provision of the second sentence of said paragraph.
(For re-examination : Article 14-5)
The Pharmaceutical Affairs Act
14
![Page 15: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/15.jpg)
Product Lifecycle
Quality Clinicaltrials
GCP
GLP
GPMSP/GPSP
Approval
Post-marketingSurveillance
Inspection
Nonclinical studies
Application for Re-examination
Inspection
New-drugApplication
GLP : Good Laboratory Practice, GCP : Good Clinical Practice, GPMSP : Good Post-marketing Surveillance Practice, GPSP : Good Post-marketing Study Practice
Pharmacovigilance
Result of Re-examination
Data reliability standards for applications
![Page 16: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/16.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
16
![Page 17: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/17.jpg)
(Reviews, etc. Performed by the PMDA)Article 14-2 (1)
The Minister of Health, Labour and Welfare may have the PMDA perform the review for approval pursuant to the provision of paragraph (1) or (9) of the preceding paragraph as well as the examinations or inspections pursuant to the provision of paragraph (5) of said Article or the examinations or inspections pursuant to the provision of paragraph (6) of said Article (including the cases where applied mutatis mutandis pursuant to paragraph (9) of said Article), with respect to those drugs (excluding those intended exclusively for use in animals; hereinafter the same shall apply in this Article), quasi-drugs (excluding those intended exclusively for use in animals; hereinafter the same shall apply in this Article), cosmetics or medical devices (excluding those intended exclusively for use in animals; hereinafter the same shall apply in this Article) which are specified by Cabinet Order.
(For re-examination : Article 14-5)
The Pharmaceutical Affairs Act
17
![Page 18: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/18.jpg)
PMDA continues to improve the public health and safety of our nation by reviewing applications for marketing approval of pharmaceuticals and medical devices, conducting safety measures, and providing relief to people who have suffered from adverse drug reactions.We conduct our mission in accordance with the following principles:
- We pursue the development of medical science while performing our duty with greater transparency based on our mission to protect public health and the lives of our citizens.
- We will be the bridge between the patients and their wishes for faster access to safer and more effective drugs and medical devices.
- We make science-based judgments on quality, safety, and efficacy of medical products by training personnel to have the latest technical knowledge and wisdom in their field of expertise.
- We play an active role within the international community by promoting international harmonization.
- We conduct services in a way that is trusted by the public based on our experiences from the past.
Our philosophy
18
![Page 19: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/19.jpg)
Organization Chart of PMDA
Office of Review Administration
Office of Review Management
Office of Medical Devices I - III
Office of New Drug I - V
Office of Biologics I - II
Office of OTC/Generic Drugs
Office of Conformity Audit
Office of Relief Funds
Office of GMP/QMS Inspection
Office of Planning and Coordination
GLP GCP
GPSP
SeniorExecutive Director
Chief Executive
Auditor
Chief Safety Officer
Executive Director
Executive Director
Office of Regulatory Science
Office of International Programs
Chief Relief Officer
(As of November 2011)
Audit Office
Information Technology Promotion Group
Chief management Officer
Chief Actuary
Associate Executive director
AssociateCenter director
AssociateCenter director
Director ofCenter for Product
Evaluation
AssociateCenter director
AssociateExecutive director
International Liaison Officers
Senior Scientists
GMP/QMS
Auditor
Office of Safety I - II
Office of General Affairs
Office of Financial Management
Office of Standards and Guidelines Development
19
![Page 20: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/20.jpg)
GCP On-siteInspection
Document-based
ConformityInspection
GLPInspection
GPSPInspection
Office Director
Office of Conformity Audit, PMDA
20
![Page 21: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/21.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
21
![Page 22: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/22.jpg)
Data Flow at Clinical Tests
・medical charts・nursing notes・examination slips・patients’ reports,
etc…
Case Report Form
Database
SDVData entry,
Data check,
Data Rectification
Data Fixation
Records
CRF
DBClinical Study Report
Statistical Analysis Report
HospitalPharmaceutical Company
![Page 23: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/23.jpg)
Source Documentsmedical charts, nursing notes, examination slips, images, etc.
Case Report Form(CRF)
Database
Statistical Analysis Report
Clinical Study Report
GCP On-site
Inspection
Document-based
Conformity Inspection
Clinical Trials Implemented in Compliance with GCP
Preparation of Clinical Study Report
![Page 24: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/24.jpg)
All information on a clinical trial should be recorded, handled and stored so as to ensure the precise reporting, interpretation and examination thereof.
Documents for the conduct of clinical trials, whether printed materials or electronic records, should be prepared on the basis of ALCOA-principle.
Attributable – Legible – Contemporaneous – Original – Accurate
Reliability of Documents for the conduct of Clinical Trials
![Page 25: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/25.jpg)
Analysis Sets and Quality of Clinical Trial①• Full Analysis Set ( FAS )The set of subjects that is as close as possible to the ideal implied by the intention-to-treat principle. It is derived from the set of all randomised subjects by minimal and justified elimination of subjects.
• Per Protocol Set ( PPS )The set of data generated by the subset of subjects who complied with the protocol sufficiently to ensure that these data would be likely to exhibit the effects of treatment, according to underlying scientific model. Compliance covers such considerations as exposure to treatment, availability of measurements and absence of major protocol violations.
![Page 26: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/26.jpg)
Analysis Sets and Quality of Clinical Trial②
• In general, clear-cut discrepancy between FAS and PPS is observed when clinical trials were not conducted in compliance with protocol or protocol had flaws.
• If the discrepancy is found, it is necessary to clarify the background and examine its potential for bias. The difference between analysis results obtained from each analysis set should also be considered.
![Page 27: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/27.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
27
![Page 28: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/28.jpg)
Major factors influencing the Quality of Clinical Trials
• ProtocolOften, quality of the protocol impacts quality
of clinical trials. Important thing is to examine closely what
kind of data to collect in the course of preparing protocols.
• Implementation system
![Page 29: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/29.jpg)
Major factors influencing the Quality of Clinical Trials
• Protocol• Implementation systemKey points are…To capture the problems on conducting clinical
trials (e.g., interpretation of inclusion criteria, exclusion criteria, etc.) as soon as possible.
To feed back the solution to all related sites.
![Page 30: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/30.jpg)
Deviation from the Protocol・The eligibility of subject was not examined appropriately.⇒Was the criteria well-defined?⇒Was the criteria reasonable from ethical and/or scientific point of view?
Findings and our point of view
![Page 31: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/31.jpg)
Deviation from the Protocol
・Noncompliance with the rules on evaluating product efficacy and/or safety
⇒Was the method and/or index for evaluation well-defined, and reasonable from the scientific point of view?
⇒Did PI(or responsible person) ask about or confirm the interpretation to the sponsor when he/she was not sure about it?
⇒Did sponsor provide the answer for the question to all related sites as necessary?
⇒Did sponsor revise the protocol as necessary?
・・・
Findings and our point of view
![Page 32: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/32.jpg)
Inappropriately obtained informed consent・Informed consent was obtained by using the not fully explained information document. ⇒Check if the IRB reviewed the document appropriately.
Findings and our point of view
![Page 33: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/33.jpg)
Inappropriately obtained informed consent・Although the written information document was revised, nor were the subjects informed in a timely manner or was the communication of this information documented.⇒Check if the subject decided to continue participation with his/her own will.
Findings and our point of view
![Page 34: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/34.jpg)
Examples of Inquiry ~Document-based Conformity Inspection~
• Background of Inconsistency between CRF and CSR, between SAR and CSR, within CSR
• Handling of ineligible subjects• Handling of subjects in efficacy analysis set• Handling of electronic data• Adequateness of timing of PI signature• The reason why the blind was broken not in
accordance with the stipulated procedure
![Page 35: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/35.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
35
![Page 36: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/36.jpg)
Spread of Electronic Documentation
・EDC(Electronic Data Capture)・eCRF(Electronic Case Report Form)
・eCTD(Electronic Common Technical Document)・Document management system・Electronic medical chart・・・etc.
Of course, We ACCEPT Electronic Documents!
We are checking・・・if the process can be described with
sufficient groundsif it is possible to clarify where
responsibility lies
![Page 37: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/37.jpg)
Quality by Design (QbD)in Clinical Trials
QbD approach is proceeding steadily in the manufacturing field.
Recently, the concept has been introduced into the field of clinical trials to ensure the quality.
![Page 38: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/38.jpg)
4th Annual Conference on Drug Discovery and Clinical Development in India | November 14-18, New Delhi, India
1. Product Lifecycle and Conformity Inspection
2. Conformity Inspection Conducted by PMDA
3. Data Flow and Quality
4. View Point of Inspection
5. From Recent Topics
6. Summary
Contents
38
![Page 39: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/39.jpg)
• Implementation of clinical trials is essential to improve the medical environment by introducing new drug(s). Data must be reliable for appropriate evaluation.
• The actual status of the drug utilization must be reflected to data collected for appropriate re-examination of approved drugs .
39
![Page 40: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/40.jpg)
We are checking・・・
If the quality is assured or not.How to assure the quality is not our major concern.
If the results and explanations are same with those from data without error.To consider errors’ impact on the results is important.
If the data is handled appropriately or not.Intentionally-handled data will be our major concern.
![Page 41: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/41.jpg)
Smooth implementation of Clinical trials
Investigators IRB/EC
Sponsors(Pharmaceutical company, etc.)
Clinical trial office
Trial collaborators(CRC)
Subjects
Cooperation is indispensable. 41
![Page 42: Data Quality - 医薬品医療機器総合機構 · Evaluation and Data Reliability. It is stipulated in Pharmaceutical Affairs Act that examination of Efficacy and Safety of the](https://reader034.vdocuments.mx/reader034/viewer/2022042023/5e7b530a2b31a641805e487e/html5/thumbnails/42.jpg)
Thank you for your [email protected]
We try to help improve public health by watching the pre-approval and post-marketing stages also from inspectors’ point of view.